“`html
Telix Pharmaceuticals (TLX) Faces Lawsuit Over Alleged Misleading Statements on Cancer Drug Growth and Supply Chain
Table of Contents
A securities class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, following significant regulatory setbacks and a subsequent decline in stock value.Investors who experienced significant losses during a defined period are being encouraged to contact the firm investigating the claims.
The lawsuit, filed in the U.S. District Court for the Southern District of Indiana, alleges that Telix and certain executives made false and misleading statements that inflated the company’s valuation before the truth regarding its progress and operations emerged. The “Class Period” for the alleged misconduct spans from February 21, 2025, to August 28, 2025, with a lead plaintiff deadline of January 9, 2026.
Core Allegations of Misconduct
The legal action centers on two primary accusations: that Telix overstated the therapeutic progress of its prostate cancer candidates, specifically TLX591 and TLX592, and that the company misrepresented the stability and regulatory compliance of its third-party supply chain and manufacturing partners. These alleged misrepresentations, according to the complaint, were crucial to the company’s regulatory applications.
Regulatory Setbacks Trigger Stock Decline
The market’s perception of Telix shifted dramatically following two key events in July and August 2025. On July 22, 2025, the company disclosed it had received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking documents related to public disclosures concerning the development of its prostate cancer therapeutics. This news led to a more than 13% drop in the price of Telix American Depositary Shares (ADSs) over two trading sessions.
The more substantial blow came on August 28,2025,when Telix announced it had received a Complete Response letter (CRL) from the U.S. food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for TLX250-cdx (Zircaix), an investigational PET imaging agent. The CRL constituted a formal rejection of the application, citing “deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package.”
Critically, the FDA also documented “notices of deficiency (Form 483)” issued to two third-party manufacturing and supply chain partners, indicating that remediation would be required before resubmission. These findings directly contradicted Telix’s earlier assurances regarding the reliability of its supply chain. Following this announcement, Telix ADSs experienced a further decline of over 21% over two trading sessions.
Hagens Berman Investigates Claims
National investor rights firm Hagens Berman is actively investigating the allegations and representing investors in the class action. “We’re looking into whether the Company knowingly misrepresented the foundational integrity of its drug development and manufacturing capabilities,” stated a partner at Hagens Berman leading the investigation, Reed Kathrein.
Investors who acquired Telix securities during the Class Period and suffered losses are encouraged to submit their losses and contact the firm at www.hbsslaw.com/investor-fraud/tlx, [email protected], or 844-916-0895. The firm is also seeking individuals with non-public information regarding Telix to assist in the investigation,perhaps
Keep reading
